Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism

Psychopharmacology

Volumn 175, Issue 1, 2004, Pages 1-6

  Melkersson, K I ^a   Dahl, M L ^b   Hulting, A L ^c  

^a Sollentuna Psychiatric Polyclinic   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antipsychotic agents; Diabetes mellitus; Guidelines; Lipid abnormalities; Treatment; Weight gain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; DRUG METABOLITE; FLUPHENAZINE; HALOPERIDOL; INSULIN; LEPTIN; LOXAPINE; NOROLANZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

CLINICAL PROTOCOL; DIABETIC KETOACIDOSIS; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERLIPIDEMIA; HYPEROSMOLAR COMA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; GLUCOSE; GLUCOSE METABOLISM DISORDERS; HOMEOSTASIS; HUMANS; INSULIN; LIPID METABOLISM; PRACTICE GUIDELINES;

EID: 4544276308     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1922-7     Document Type: Review

References (52)

1. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP et al (1999a) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60:215-220
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999b) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
3. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598-604
4. Baptista T (1999) Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 100:3-16
5. Braceland FJ, Meduna LJ, Vaichulis JA (1945) Delayed action of insulin in schizophrenia. Am J Psychiatry 102:108-110
6. Brady KT (1989) Weight gain associated with psychotropic drugs. South Med J 82:611-617
7. Clark M, Dubowski K, Colmore J (1970) The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharm Ther 11:883-889
8. Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP (1972) Evaluation of loxapine succinate in chronic schizophrenia. Dis Nerv Syst 33:783-791
9. Dahl M-L (2002) Cytochrome P 450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing ? Clin Pharmacokinet 41:453-470
10. Dursun SM, Szemis A, Andrews H, Revely MA (1999) The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 24:453-455
11. Fenton WS (2000) Review: most antipsychotic drugs are associated with weight gain. Evid Based Ment Health 3:58
12. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL (1999) Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 156:1270-1272
13. Gilbert PL, Harris J, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52:173-188
14. Gopalaswamy AK, Morgan R (1985) Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 72:254-258
15. Gordon HL, Law A, Hohman KE, Groth C (1960) The problem of overweight in hospitalized psychotic patients. Psychiatr Q 34:69-82
16. Haupt DW, Newcomer JW (2001) Hyperglycemia and antipsychotic medications. J Clin Psychiatry 62(suppl 27):15-26
17. Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS (2004) A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 161:361-363
18. Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287-302
19. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR (2003) Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine (letter). J Clin Psychiatry 64:1133-1134
20. Klett CJ, Caffey EM (1960) Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 2:102-108
21. Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852
22. Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716-723
23. Koller EA, Cross JT, Doraiswamy PM, Schneider BS (2003) Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23:735-744
24. Luna B, Feinglos MN (2001) Drug-induced hyperglycemia. JAMA 286:1945-1948
25. Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ (1958) Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J Nerv Ment Dis 127:167-179
26. Melkersson K (2004) Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 14:115-119
27. Melkersson KI, Dahl M-L (2003) Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 170:157-166
28. Melkersson K, Dahl M-L (2004) Adverse metabolic effects of atypical antipsychotics - literature review and clinical implications. Drugs 64:701-723
29. Melkersson KI, Hulting A-L (2001) Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 154:205-212
30. Melkersson KI, Hulting A-L, Brismar KE (1999) Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 60:783-791
31. Melkersson KI, Hulting A-L, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749
32. Melkersson K, Kahn A, Hilding A, Hulting A-L (2001) Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 11:327-332
33. Meyer JM (2001) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374
34. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73
35. Olefsky JM (1997) Insulin resistance. In: Porte D, Sherwin RS (eds) Diabetes mellitus, 5th edn. Appleton & Lange, Stamford, pp 513-552
36. Osser DN, Najarian DM, Dufresne RL (1999) Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767-770
37. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595-1607
38. Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA (1999) Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin Drug Invest 18:99-104
39. Russell JM, Mackell JA (2001) Bodyweight gain associated with atypical antipsychotics. Epidemiology and therapeutic implications. CNS Drugs 15:537-551
40. Ryan MCM, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284-289
41. Segal KR, Landt M, Klein S (1996) Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 45:988-991
42. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C (1999) Olanzapine-induced elevation of plasma triglyceride levels (letter). Am J Psychiatry 156:1471-1472
43. Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I et al (1999) The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 22:98-101
44. Stanton JM (1995) Weight gain associated with neuroleptic medication: a review. Schizophr Bull 21:463-472
45. Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101:416-432
46. Taylor D, Paton C, Kerwin R (2003) Monitoring metabolic effects of antipsychotics. In: Dunitz M (ed) The Maudsley prescribing guidelines, 7th edn. Taylor & Francis, London, pp 72-74, 80-82
47. Thonnard-Neumann E (1968) Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 124:978-982
48. Tollefson G, Lesar T (1983) Nonketotic hyperglycemia associated with loxapine and amoxapine: a case report. J Clin Psychiatry 44:347-348
49. Wetterling T (2001) Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 24:59-73
50. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865
51. Woods SC, Kaiyala K, Porte D, Schwartz MW (1997) Food intake and energy balance. In: Porte D, Sherwin RS (eds) Diabetes mellitus, 5th edn. Appleton & Lange, Stamford, pp 175-192
52. Zirnmet PZ (1992) Kelly West Lecture 1991. Challenges in diabetes epidemiology: from West to the rest. Diabetes Care 15:232-252